慢性淋巴细胞白血病
医学
布鲁顿酪氨酸激酶
伊布替尼
耐火材料(行星科学)
威尼斯人
肿瘤科
临床试验
白血病
突变
内科学
免疫学
癌症研究
生物
遗传学
酪氨酸激酶
受体
天体生物学
基因
标识
DOI:10.1016/j.hoc.2021.04.001
摘要
Despite recent success in regard to targeted therapies in chronic lymphocytic leukemia (CLL), patients with TP53 disruption (including deletion and/or mutation) continue to have poor outcomes compared with other patients with CLL. In this article, a review of common TP53 mutations in CLL, and recent trials using novel targeted agents in CLL patients with TP53 disruption, is provided with the goal of emphasizing the need to continuously focus on this area of research. In addition, limited but available data on double refractory CLL to BTK inhibitor and BCL-2 inhibitor, and on Richter syndrome, are reviewed.
科研通智能强力驱动
Strongly Powered by AbleSci AI